Stifel Nicolaus Reaffirms “Buy” Rating for Valeant Pharmaceuticals International, Inc. (VRX)

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX)‘s stock had its “buy” rating reiterated by analysts at Stifel Nicolaus in a report issued on Thursday. They currently have a $35.00 price objective on the specialty pharmaceutical company’s stock. Stifel Nicolaus’ price objective would suggest a potential upside of 148.76% from the company’s previous close.

A number of other equities research analysts have also recently commented on the company. Wells Fargo & Company reiterated an “underperform” rating and set a $9.00 target price on shares of Valeant Pharmaceuticals International in a report on Thursday. Canaccord Genuity set a $14.00 target price on Valeant Pharmaceuticals International and gave the company a “hold” rating in a report on Thursday. Mizuho reiterated an “underperform” rating and set a $8.00 target price on shares of Valeant Pharmaceuticals International in a report on Wednesday. Scotiabank increased their target price on Valeant Pharmaceuticals International from $14.00 to $16.00 and gave the company a “sector perform” rating in a report on Wednesday. Finally, HC Wainwright set a $17.00 target price on Valeant Pharmaceuticals International and gave the company a “hold” rating in a report on Wednesday. Four research analysts have rated the stock with a sell rating, fourteen have issued a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. Valeant Pharmaceuticals International has an average rating of “Hold” and an average target price of $17.26.

Valeant Pharmaceuticals International (VRX) opened at 14.07 on Thursday. The firm’s 50-day moving average price is $16.61 and its 200-day moving average price is $13.38. The firm’s market cap is $4.90 billion. Valeant Pharmaceuticals International has a 1-year low of $8.31 and a 1-year high of $32.74.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last announced its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 EPS for the quarter, beating analysts’ consensus estimates of $0.97 by $0.08. The firm had revenue of $2.23 billion for the quarter, compared to analysts’ expectations of $2.23 billion. Valeant Pharmaceuticals International had a positive return on equity of 60.62% and a negative net margin of 12.40%. Valeant Pharmaceuticals International’s quarterly revenue was down 7.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.88) EPS. On average, equities research analysts anticipate that Valeant Pharmaceuticals International will post $3.89 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This report was published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this report on another publication, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this report can be read at https://www.tickerreport.com/banking-finance/2797319/stifel-nicolaus-reaffirms-buy-rating-for-valeant-pharmaceuticals-international-inc-vrx.html.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Morgan Stanley raised its position in Valeant Pharmaceuticals International by 48.2% in the first quarter. Morgan Stanley now owns 2,777,063 shares of the specialty pharmaceutical company’s stock valued at $30,631,000 after buying an additional 903,256 shares during the period. Raymond James Financial Services Advisors Inc. raised its position in Valeant Pharmaceuticals International by 61.2% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 41,414 shares of the specialty pharmaceutical company’s stock valued at $457,000 after buying an additional 15,719 shares during the period. Gabelli Funds LLC bought a new position in Valeant Pharmaceuticals International during the first quarter valued at approximately $331,000. Bogle Investment Management L P DE bought a new position in Valeant Pharmaceuticals International during the first quarter valued at approximately $11,223,000. Finally, Guggenheim Capital LLC raised its position in Valeant Pharmaceuticals International by 18.6% in the fourth quarter. Guggenheim Capital LLC now owns 17,540 shares of the specialty pharmaceutical company’s stock valued at $255,000 after buying an additional 2,752 shares during the period. 51.14% of the stock is currently owned by institutional investors.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.